Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Emergent Biosolutions (NY: EBS ) 6.170 UNCHANGED Streaming Delayed Price Updated: 7:00 PM EDT, Jun 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Emergent Biosolutions < Previous 1 2 3 4 5 6 7 8 9 Next > A Preview Of Emergent BioSolutions's Earnings April 28, 2021 Emergent BioSolutions (NYSE:EBS) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings... Via Benzinga Is There Any Hope Left for Emergent BioSolutions? April 27, 2021 The go-to government contractor is in deep trouble. Should investors buy the dip? Via The Motley Fool Exposures COVID-19 The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx April 24, 2021 Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... Via Benzinga Exposures Product Safety JNJ's COVID-19 Vaccine Halt Due To Blood-Clot Concerns To Be Scrutinized Today: WSJ April 23, 2021 The U.S. is expected to announce its decision on Johnson & Johnson’s (NYSE: JNJ) single-shot COVID-19 vaccine on whether it should be back in circulation... Via Benzinga Exposures COVID-19 12 Health Care Stocks Moving In Thursday's Intraday Session April 22, 2021 Gainers Renalytix AI (NASDAQ:RNLX) shares rose 21.41% to $30.62 during Thursday's regular session. Renalytix AI's stock is trading at a volume of 1.0 million... Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Why Emergent BioSolutions Stock Is Falling Again Today April 22, 2021 An analyst lowered his price target on the stock. Via The Motley Fool Exposures COVID-19 Stocks That Hit 52-Week Lows On Thursday April 22, 2021 On Thursday morning, 5 companies achieved new lows for the year. Interesting Points: Emergent BioSolutions (NYSE:EBS) was the largest, in terms of market cap, to... Via Benzinga FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training April 21, 2021 The FDA concluded its inspection of Emergent BioSolutions Inc’s (NYSE: EBS) troubled vaccine manufacturing plant in Baltimore after it stopped... Via Benzinga Exposures COVID-19 Product Safety The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs April 22, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,... Via Benzinga House Democrats Investigating Emergent BioSolutions' Vaccine Contracts, Call On Execs To Testify April 21, 2021 A congressional panel has launched an investigation into whether Emergent BioSolutions Inc (NYSE: EBS) was improperly awarded a $628 million federal... Via Benzinga The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue April 21, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,... Via Benzinga EMA Finds Potential Blood Clot Link With JNJ COVID-19 Shot, Adds Safety Warning April 20, 2021 The European Medicines Agency’s (EMA) safety committee said that the Johnson & Johnson’s (NYSE: JNJ) COVID-19 vaccine has possible links to... Via Benzinga Exposures COVID-19 Emergent BioSolutions Stock Falls After FDA Initiates Inspection Of Bayview Facility April 19, 2021 Emergent BioSolutions Inc (NYSE: EBS) has had a tough month: First, the company ruined 15 million doses of Johnson & Johnson’s (NYSE:... Via Benzinga Exposures Product Safety Why Emergent BioSolutions Stock Is Tumbling Today April 19, 2021 The company has halted production of COVID-19 vaccines at its Baltimore facility as an FDA inspection moves forward. Via The Motley Fool Exposures COVID-19 Product Safety Why Emergent BioSolutions Stock Fell Today April 13, 2021 The pause on use of Johnson & Johnson's COVID-19 vaccine had a ripple impact. Via The Motley Fool Exposures COVID-19 Johnson & Johnson's COVID-19 Vaccine Under Review At EMA For Blood Clots, AstraZeneca Probe Expanded April 09, 2021 AstraZeneca Plc’s (NASDAQ: AZN) COVID-19 vaccine has recently dominated headlines after cases of rare blood clots were reported in European countries. Now,... Via Benzinga Exposures COVID-19 Trouble Is Brewing For J&J's Covid Vaccine — What You Need To Know April 09, 2021 European regulators are investigating four cases of blood clots in recipients of J&J's coronavirus vaccine. In response, JNJ stock dipped Friday. Via Investor's Business Daily Exposures COVID-19 US Allocates Significantly Lower Number Of J&J Vaccines To States For Next Week: Reuters April 08, 2021 The U.S. government will allot around 85% less Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccines to states next week, data from the Centers for Disease... Via Benzinga Exposures COVID-19 AstraZeneca Stock Plagued As Issues Continue To Mount For Covid Vaccine April 07, 2021 AstraZeneca stock dipped Wednesday after European regulators found a possible link between the company's Covid vaccine and rare cases of blood clots. Via Investor's Business Daily 31 Stocks Moving in Thursday's Pre-Market Session April 01, 2021 Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) rose 44.4% to $10.73 in pre-market trading after the company, and EMC Pharma, announced an exclusive partnership to expand... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2021 April 07, 2021 Upgrades According to Janney Capital, the prior rating for Texas Capital Bancshares Inc (NASDAQ:TCBI) was changed from Neutral to Buy. Texas Capital Bancshares earned $1.... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.